The mental faculties a biotech CEO needs most are the first to degrade under chronic pressure. This is not a character issue, ...

Patent attorney Eric M. Brusca, Ph.D., explains how biopharmaceutical companies and their IP law firms can cultivate ...

Life Science Cares, an industry philanthropic organization, turns 10 in April. Now in five cities and Switzerland, the organization remains focused on fighting poverty.

On this week's episode of the Business of Biotech, Rob Abbott, CEO of ISPOR, explains how startup and early-stage clinical drug development companies benefit from conducting health economics and ...

At a time of continuous change and increasing complexity, success for life sciences companies will largely depend on how they support, nurture and develop their teams. But even that has gotten more ...

Life sciences startups have long felt the gravitational pull of Boston and San Francisco when looking to raise capital, expand, and recruit talent. These two coastal regions, with an established ...

In biotech, partnerships are often viewed as milestones - announcements that validate a technology or provide funding for the next stage of development. For platform companies, however, collaborations ...

Predicting how cells behave in a bioreactor is one of the more demanding challenges in biologics manufacturing. Classical data-driven models offer a practical starting point, but they rely on fitting ...

Clinical trials rely on timely patient enrollment, yet up to 85% of studies fail to recruit or retain enough participants, leading to costly delays and missed market opportunities. To overcome this, ...

Regulatory submissions are entering a period of meaningful structural change. eCTD 4.0 is gaining traction at both the FDA and EMA, offering practical improvements over its predecessor: more flexible ...

The EU Health Technology Assessment regulation's first year has revealed important patterns for manufacturers preparing joint clinical assessments. PICO consolidation remains complex, requiring ...